Regeneron's dispute with Mylan over Eylea-related patent claims belongs in the life-sciences archive because formulation wording did real work.
The Federal Circuit analyzed claim language listing a VEGF antagonist and buffer, with the parties disputing whether separately recited elements must be treated as distinct.
For biologics and biosimilar-adjacent portfolios, the case is a reminder that formulation claims can turn on grammar, specification context, and how the court reads listed components.
This article is tagged to the life-sciences archive because the dispute reflects the kind of drug-patent claim drafting issue that carries into later launch strategy.